A first-in-man experience of the Enabler-P Balloon Catheter System (EndoCross) has shown positive outcomes in the treatment of peripheral artery disease. The results of the study were published in the current issue of the Journal of Endovascular Therapy.
Medtronic has announced the availability of the Valiant Captivia Thoracic Stent Graft System for endovascular repair of aortic aneurysms in China, Japan and the United States.
Two types of stent systems are both effective in treating patients who have severe forms of peripheral artery disease, according to results of the MOBILITY trial presented by Michael R Jaff , Boston, USA, on 10 May as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2012 Scientific Sessions in Las Vegas, USA.
Michael Gough, Leeds General Infirmary, Leeds, UK, presented long-term follow-up after endovenous laser ablation for great saphenous varicose veins at the 34th Charing Cross International Symposium in London, UK. The study reviewed a group of 63 patients (79 limbs) 6.5 years after above-knee laser treatment.
NATICK, Mass., May 17, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration approval and market launch of the Epic Vascular Self-Expanding Stent System. The Epic Stent is designed to open blocked arteries in patients with iliac artery stenosis, a form of peripheral vascular disease associated with severe leg pain caused by insufficient blood flow.
LAS VEGAS -- Most patients with aorto-iliac disease should be treated endovascularly with stents rather than surgically, a researcher suggested after presenting results of the MOBILITY trial.
Excellent Primary Patency at 6 Months for the 4EVER Study Using the Pulsar Stent System With PROBIO Coating
Cardiovascular Systems (CSI) has announced two new partnerships broadening the company’s product portfolio. According to a company release, CSI is now the exclusive US distributor of OrbusNeich balloon products. Additionally, the company has signed an original equipment manufacturer agreement with Integer Holdings Corporation for CSI-branded ZILIENT guidewires.
The new European Directive laying down basic safety standards for protection against the dangers arising from ionising radiation exposure will come into effect on 6 February 2018. The most relevant change for interventionists in the occupational exposure section is the new annual limit for the lens of the eyes (20 mSv/year, instead of 150 mSv/year), write Eliseo Vano (Madrid, Spain) and Gabriel Bartal (Kfar Saba, Israel).
Janssen Pharmaceuticals has announced that the FDA has approved the 10mg once-daily dose of rivaroxaban (Xarelto) for reducing the continued risk for recurrent venous thromboembolism (VTE) after completing at least six months of initial anticoagulation therapy.
Philips has announced the results of a comprehensive, independent, two-year study demonstrating the clinical workflow benefits of its next generation image-guided therapy platform, Azurion.
The Society of Interventional Radiology (SIR), in coordination with Member of the US House of Representatives (Rep.) from Utah’s 4th district, Mia Love, hosted a panel discussion on the important role of interventional radiologists on trauma teams responding to mass casualty incidents.
Intact Vascular has announced that positive single centre twenty-four month results from its TOBA (Tack optimised balloon angioplasty) clinical study were presented at VEITHsymposium 2017 by Christian Wissgott, assistant director, Westküstenklinikum Heide in Heide, Germany.
Paolo Zamboni, Ferrara, Italy, the proponent of the chronic cerebrospinal venous insufficiency (CCSVI) theory, and his colleagues have reported that the randomised, double-blinded, sham controlled Brave Dreams trial has not demonstrated a benefit for venous angioplasty in the treatment of patients with multiple sclerosis (MS).
The Global Medtech industry is moving together to enhance compliance practices across Europe, China, the Middle East, North Africa and Asia-Pacific, announces a statement released by AdvaMed, APACMed, Mecomed, and MedTech Europe.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos